Ninety-six patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) (0.4 mg/kg orally, day 6) plus prednime (PDN) (60 mg/m2 orally, days 1-5) every 2 weeks or cyclophosphamide (600 mg/
✦ LIBER ✦
Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia
✍ Scribed by The French Cooperative Group on CLL; S Johnson; A.G Smith; H Löffler; E Ösby; G Juliusson; B Emmerich; P.J Wyld; W Hiddemann
- Book ID
- 118562127
- Publisher
- The Lancet
- Year
- 1996
- Tongue
- English
- Weight
- 1000 KB
- Volume
- 347
- Category
- Article
- ISSN
- 0140-6736
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Treatment of chronic lymphocytic leukemi
✍
Emilio Montserrat; Antonio Alcalá; Ricardo Parody; Andreu Domingo; Javier García
📂
Article
📅
1985
🏛
John Wiley and Sons
🌐
English
⚖ 685 KB
High dose chlorambucil versus Binet's mo
✍
Branimir Jaksic; Maura Brugiatelli; Ivo Krc; Hajna Losonczi; Jerzy Holowiecki; A
📂
Article
📅
1997
🏛
John Wiley and Sons
🌐
English
⚖ 115 KB
👁 2 views
vanced and/or progressive disease was defined by high Total Tumor Mass (TTM) score (ú9), and/or short doubling time (DT) (õ12 months), and/or bone marrow for the International Society for Chemo-Immunotherapy, Vienna failure. The response to therapy was defined by reduction of the initial TTM score.